Bladder adenocarcinoma differs from epidermoid carcinoma of the bladder in terms of origin and extent of lesions. Bladder tumors are the most common genitourinary malignancies in China. Clinically, bladder tumors are mostly uroepithelial tumors, and non-urinary bladder epithelial tumors (NUBCs) account for 5% to 7% of bladder tumors. According to tissue type, NUBC can be divided into tumors of epithelial origin and non-epithelial origin. Tumors of epithelial origin include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma, while tumors of non-epithelial origin include sarcoma, carcinosarcoma, paraganglioma, melanoma, and lymphoma. Epidermoid carcinoma of the bladder usually refers to tumors originating from the bladder epithelium, mainly uroepithelial carcinoma. In contrast, adenocarcinoma is also a tumor of epithelial origin, but of glandular cellular origin and is clinically rare. Some studies claim that the 3-year overall survival rates of umbilical ureter adenocarcinoma and umbilical ureter adenocarcinoma groups are 50.6% and 66.9%, respectively; whereas the prognosis of patients with uroepithelial carcinoma is relatively better, with some studies claiming that the survival rates of 1 year, 3 years, and 5 years are 95.12%, 82.14%, and 63.12%, respectively. It is suggested that patients should consult doctor for examination in time, carry out targeted treatment after clarifying the cause of the disease, pay attention to observing the condition in life, and have regular rechecks to avoid metastasis of cancer cells.